Copenhagen, Denmark-based Orphazyme announced the company’s Phase II/III clinical trial of arimoclomal for inclusion body myositis (IBM) failed to hit primary and secondary endpoints.
https://www.pharmalive.com/wp-content/uploads/2021/03/Orphazyme-Drug-Misses-Both-Endpoints-in-Rare-Muscle-Wasting-Disease-Trial-BioSpace-3-29-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-03-29 11:04:232021-03-29 11:11:20Orphazyme Drug Misses Endpoints in Rare Muscle-Wasting Disease Study